Rifampin plus Clindamycin vs. Tetracyclines for Hidradenitis Suppurativa
Clinical & Experimental Dermatology and Therapies · 2022
DOI: 10.29011/2575-8268.100187 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical & Experimental Dermatology and Therapies, 2022.
Abstract (Originalsprache)
Introduction
Hidradenitis suppurativa (HS) is a chronic, painful, follicular occlusive disease that affects the follicular pilosebaceous unit.It is typically apparent in intertriginous areas, causing abscesses, sinus tract formation, and scarring.Recent guidelines for the management of HS recommend oral treatment with a combination of clindamycin and rifampin for widely spread lesions, although very few studies assessing the efficacy of this combination and its comparison with tetracyclines have been conducted.Hence, this study was aimed at comparatively evaluating the efficacy of the combination of clindamycin and rifampin with that of tetracyclines for the management of HS.
Methods
We retrospectively evaluated patients diagnosed with HS between 2010 and 2020 at the outpatient dermatology clinics of Sheba Medical Center.The data collected included patients' demographic characteristics (age, sex, and weight); disease stage, including that before, during, and after treatment; treatment period; remission period; flare-ups; treatment failures; and side effects.
Results
In all, 137 patients including 70 (51.09%) men and 67 (48.9 %) women were diagnosed with HS; the patients' mean age was 42.4 ± 14.6 years.Among them, 52 patients were treated with a combination of clindamycin and rifampin and 26 were treated with tetracyclines.Thirty-two (61.5 %) and 3 (5.7 %) of the 52 patients treated with clindamycin and rifampin achieved complete and partial remission, respectively.Six of the 26 patients treated with tetracyclines (23 %) achieved complete remission.Tetracyclines were less effective compared to the combination treatment (p < 0.01).However, both treatments were less effective against more severe forms of the disease.In the rifampin clindamycin group, the mean remission period was longer (13.6 ± 12.6 months) among those treated for 10 weeks or more.However, the difference in the mean remission period between those treated for 10 weeks or more and fewer than 10 weeks in this group was not significant.Non-smokers showed a better treatment response than that shown by active smokers (complete remission: 73.9 % vs. 51.7 %; p < 0.01).
Conclusion
Treatment with the combination of oral rifampin and clindamycin is effective, mainly against mild-to-moderate HS, and afforded better results than did tetracycline treatment.
Zitieren
APA
(2022). Rifampin plus Clindamycin vs. Tetracyclines for Hidradenitis Suppurativa. Clinical & Experimental Dermatology and Therapies. https://doi.org/10.29011/2575-8268.100187
Vancouver
Rifampin plus Clindamycin vs. Tetracyclines for Hidradenitis Suppurativa. Clinical & Experimental Dermatology and Therapies. 2022. doi:10.29011/2575-8268.100187
BibTeX
@article{euvimed2022,
title = {Rifampin plus Clindamycin vs. Tetracyclines for Hidradenitis Suppurativa},
journal = {Clinical & Experimental Dermatology and Therapies},
year = {2022},
doi = {10.29011/2575-8268.100187}
}
EUVIMED